By Evan McCulloch, Portfolio Manager, Director of Equity Research, Franklin Equity Group; Akiva Felt, Portfolio Manager, Research Analyst, Franklin Equity Group; and Wendy Lam, Ph.D., Portfolio Manager, Research Analyst, Franklin Equity Group
The
Biotech Innovations Remain At Forefront
Summary
- The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February.
- While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.
- We also see opportunities at the other end of the "prevalence spectrum" in addressing rare diseases.
Franklin Resources, Inc. [NYSE:BEN] is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. Through its specialist investment managers, the company offers specialization on a global scale, bringing extensive capabilities in fixed income, equity, alternatives and multi-asset solutions. With more than 1,300 investment professionals, and offices in major financial markets around the world, the California-based company has over 75 years of investment experience and over $1.4 trillion in assets under management as of June 30, 2023. For more information, please visit franklintempleton.com and follow us on LinkedIn, Twitter and Facebook.